Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts

Liver Transplantation

Volumn 18, Issue 11, 2012, Pages 1333-1342

  Miyagawa Hayashino, Aya ^a   Yoshizawa, Atushi ^a   Uchida, Yoichiro ^a   Egawa, Hiroto ^b   Yurugi, Kimiko ^a   Masuda, Satohiro ^c   Minamiguchi, Sachiko ^a   Maekawa, Taira ^a   Uemoto, Shinji ^a   Haga, Hironori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ARTICLE; CHILD; DONOR; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES; BILIARY ATRESIA; CHILD; CHILD, PRESCHOOL; COMPLEMENT C4B; FEMALE; FIBROSIS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868115525     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23534     Document Type: Article

References (35)

1. Sakashita H, Haga H, Ashihara E, Wen MC, Tsuji H, Miyagawa-Hayashino A, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684.
2. Ashihara E, Tsuji H, Sakashita H, Haga H, Yurugi K, Kimura S, et al. Antidonor antibody in patients receiving ABO-identical and HLA-mismatched living donor liver transplants: effect on survival. Transplantation 2007; 83: 506-509.
3. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
4. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI,. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308-313.
5. Lunz J, Ruppert KM, Cajaiba MM, Isse K, Bentlejewski CA, Minervini M, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171-182.
6. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
7. Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
8. Kasahara M, Kiuchi T, Takakura K, Uryuhara K, Egawa H, Asonuma K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection. Transplantation 1999; 67: 568-575.
9. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M,. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858-859.
10. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
11. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
12. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
13. Ekong UD, Melin-Aldana H, Seshadri R, Lokar J, Harris D, Whitington PF, Alonso EM,. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl 2008; 14: 1582-1587.
14. Scheenstra R, Peeters PM, Verkade HJ, Gouw AS,. Graft fibrosis after pediatric liver transplantation: ten years of follow-up. Hepatology 2009; 49: 880-886.
15. Martin SR, Russo P, Dubois J, Alvarez F,. Centrilobular fibrosis in long-term follow-up of pediatric liver transplant recipients. Transplantation 2002; 74: 828-836.
16. Fouquet V, Alves A, Branchereau S, Grabar S, Debray D, Jacquemin E, et al. Long-term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center. Liver Transpl 2005; 11: 152-160.
17. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
18. Watson R, Kozlowski T, Nickeleit V, Woosley JT, Schmitz JL, Zacks SL, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
19. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
20. Ali S, Ormsby A, Shah V, Segovia MC, Kantz KL, Skorupski S, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol 2011; 26: 62-69.
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; for Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
22. Goodman ZD,. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598-607.
23. Banff Working Group, Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501.
24. Nakazawa Y, Walker NI, Kerlin P, Steadman C, Lynch SV, Strong RW, Clouston AD,. Clinicopathological analysis of liver allograft biopsies with late centrilobular necrosis: a comparative study in 54 patients. Transplantation 2000; 69: 1599-1608.
25. Krasinskas AM, Ruchelli ED, Rand EB, Chittams JL, Furth EE,. Central venulitis in pediatric liver allografts. Hepatology 2001; 33: 1141-1147.
26. Khettry U, Backer A, Ayata G, Lewis WD, Jenkins RL, Gordon FD,. Centrilobularhistopathologic changes in liver transplant biopsies. Hum Pathol 2002; 33: 270-276.
27. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
28. Colvin RB, Smith RN,. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
29. Bellamy CO,. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls. Liver Transpl 2011; 17: 747-750.
30. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ,. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749.
31. Regele H, Böhmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
32. Girnita A, Mazariegos GV, Castellaneta A, Reyes J, Bentlejewski C, Thomson AW, Zeevi A,. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2010; 71: 274-276.
33. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
34. Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl 2008: 229-239.
35. Everly MJ, Terasaki PI,. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol 2009; 70: 655-659.